Jyothy Laboratories faces crude cost pressure despite strong Fabric Care growth

Investment View and Valuation

In its August 12, 2026 results update, Motilal Oswal Financial Services retained its Neutral rating on Jyothy Laboratories after a weak 1QFY27 and a more challenging near-term margin outlook. The broker has set a target price of Rs 210, based on 20 times March 2028E P/E, compared with the current market price of Rs 200.

Motilal Oswal remains cautious because strong competitive intensity from category leaders may constrain sales growth and pricing. Sharp inflation in crude oil and derivatives is also increasing cost pressure, while the recovery in Jyothy Laboratories' margins appears delayed and more vulnerable in the prevailing high-cost environment.

1QFY27 Operating Performance

Jyothy Laboratories reported 1QFY27 revenue growth of 3 per cent year on year to Rs 7,734 million, below Motilal Oswal's estimate of Rs 8,052 million. Reported volume growth was flat, compared with the broker's expectation of 7 per cent and 11 per cent in 4QFY26.

The agreement with Henkel for Pril and FA products was discontinued effective May 31, 2026, although reported quarterly sales included those brands up to that date. Excluding Pril and FA, value growth was 8 per cent and volume growth was 5 per cent.

Segment Performance

Fabric Care was the key positive, growing 14 per cent in value and 10 per cent in volume. Performance was supported by double-digit detergent powder growth and strong liquid detergent demand across Henko, Ujala, Mr. White and Moonlight.

Home Care revenue declined 9 per cent year on year, but grew 2.4 per cent excluding Pril. The new Exo bio-enzyme liquid made an encouraging initial start, although management expects a clearer assessment of its scale-up and channel expansion only toward the end of FY27. The wider Exo franchise grew in the mid-to-high single digits in value and double digits in volume.

Personal Care revenue was flat, affected by 9-10 per cent price increases and supply-chain disruption. Management expects recovery from 2QFY27, while Margo posted modest growth. Household insecticides were affected by an extended summer and delayed rainfall. Maxo incense sticks were launched in July.

Profitability and Earnings Miss

Profitability materially missed expectations as higher raw-material costs compressed margins.

Fabric Care EBIT margin contracted 960 basis points to 9.6 per cent, while Home Care EBIT margin fell 1,200 basis points to 2.9 per cent. Personal Care EBIT margin increased 170 basis points to 13.4 per cent.

Cost Inflation and Margin Recovery

Management stated that around 90 per cent of Jyothy Laboratories' business is linked to crude oil prices, while raw-material costs increased by around 30-35 per cent. Cumulative price increases of 4-4.5 per cent have been taken, with around 3 per cent reflected in 1QFY27 and the balance expected in 2QFY27.

Management said price actions have not fully offset inflation because pricing remains broadly at par with competitors, and aggressive increases could hurt volumes in a weak demand environment. Higher-cost inventory and contracted purchases are expected to affect 2QFY27.

Management expects a gradual margin recovery, with more meaningful benefits from October if crude and other commodity prices remain stable. It is pursuing cost optimisation, procurement efficiencies, supply-chain improvements, value engineering, selective pricing and mix improvement. Advertising and promotion spending was moderated to 6.5 per cent of revenue from 7.8 per cent a year earlier, although management plans to raise brand-building investment over time.

Demand, Distribution and FY27 Outlook

Management targets double-digit FY27 revenue growth excluding Pril, supported by high-single-digit volume growth and 3-4 per cent pricing. Rural demand remained relatively resilient, whereas urban demand and General Trade stayed subdued. Modern Trade, e-commerce and quick commerce remained strong, with e-commerce and quick commerce growing around 25-30 per cent.

Motilal Oswal now models FY27E EBITDA margin of 12.4 per cent and FY28E EBITDA margin of 15.4 per cent. The broker cut FY27E EPS by 18 per cent and FY28E EPS by 3 per cent, primarily because of the margin miss caused by higher raw-material prices.

Key Risks

• Sustained crude-linked inflation and delayed cost pass-through.
• Continued impact from high-cost inventory and contracted purchases.
• Weak urban demand and subdued General Trade performance.
• Intense competition that may constrain pricing and sales growth.
• Slower-than-expected margin recovery.